First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Cited by (1,001)

Items 301–400 of 1,001

1. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
   Yuko Oya, Tatsuya Yoshida, Hiroaki Kuroda, Masashi Mikubo, Chiaki Kondo, Junichi Shimizu, Yoshitsugu Horio, Yukinori Sakao, Toyoaki Hida, Yasushi Yatabe · 2017 · Oncotarget
2. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis
   Fausto Petrelli, Raffaele Ardito, Karen Borgonovo, Veronica Lonati, Mary Cabiddu, Mara Ghilardi, Sandro Barni · 2018 · European Journal of Cancer
3. Mining TCGA database for tumor mutation burden and their clinical significance in bladder cancer
   Jia Lv, Yongze Zhu, Alin Ji, Qi Zhang, Guodong Liao · 2020 · Bioscience Reports
4. CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer
   Stanley I. Gutiontov, William Tyler Turchan, Liam Flinn Spurr, Sherin Juliet Rouhani, Carolina Soto Chervin, George Steinhardt, Angela M. Lager, Pankhuri Wanjari, Renuka Malik, Philip P. Connell et al. · 2021 · Scientific Reports
5. Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real‐life analysis of three larger gene panels
   Volker Endris, Ivo Buchhalter, Michael Allgäuer, Eugen Rempel, Amelie Lier, Anna‐Lena Volckmar, Martina Kirchner, Moritz von Winterfeld, Jonas Leichsenring, Olaf Neumann et al. · 2018 · International Journal of Cancer
6. Vitamin D Supplementation and Survival of Patients with Non–small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial
   Tadashi Akiba, Toshiaki Morikawa, Makoto Odaka, Takeo Nakada, Noriki Kamiya, Makoto Yamashita, Mitsuo Yabe, Takuya Inagaki, Hisatoshi Asano, Shohei Mori et al. · 2018 · Clinical Cancer Research
7. Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer
   Masahiro Katsurada, Tatsuya Nagano, Motoko Yoshikawa TACHIHARA, Tatsunori Kiriu, Koichi Furukawa, KIYOKO KOYAMA, Takehiro Otoshi, Reina Sekiya, Daisuke Hazama, Daisuke Tamura et al. · 2019 · Anticancer Research
8. Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
   Laura Boyero, Amparo Sánchez-Gastaldo, Miriam D. Alonso, José Francisco Noguera-Uclés, Sonia Molina‐Pinelo, Reyes Bernabé · 2020 · Cancers
9. Immunotherapy in endometrial cancer: rationale, practice and perspectives
   Wenyu Cao, Xinyue Ma, Jean Victoria Fischer, Chenggong Sun, Beihua Kong, Qing Hua Zhang · 2021 · Biomarker Research
10. Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?
    Simon Heeke, Paul M Hofman · 2018 · Translational Lung Cancer Research
11. New insight in endocrine-related adverse events associated to immune checkpoint blockade
    Giusy Elia, Silvia Martina Ferrari, Maria Rosaria Galdiero, Francesca Ragusa, Sabrina Rosaria Paparo, Ilaria Ruffilli, Gilda Varricchi, Poupak Fallahi, Alessandro Antonelli · 2019 · Best Practice & Research Clinical Endocrinology & Metabolism
12. Toxicity in combination immune checkpoint inhibitor and radiation therapy: A systematic review and meta-analysis
    Congzhou Mike Sha, Eric J. Lehrer, Clara Hwang, Daniel Michael Trifiletti, Heath B. Mackley, Joseph J. Drabick, Nicholas George Zaorsky · 2020 · Radiotherapy and Oncology
13. Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors
    Regan Michelle Memmott, Adam R. Wolfe, David Paul Carbone, Terence Marques Williams · 2021 · Journal of Thoracic Oncology
14. A machine learning approach for somatic mutation discovery
    Derrick E. Wood, James Robert White, Andrew P. Georgiadis, Beth Van Emburgh, Sonya T. Parpart-Li, Jason Mitchell, Valsamo Anagnostou, Noushin Niknafs, Rachel Karchin, Eniko Papp et al. · 2018 · Science Translational Medicine
15. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors
    Ernest Nadal, Bartomeu Massutí, Manuel Dómine, Rosario García‐Campelo, Manuel Cobo, Enriqueta Felip · 2019 · Cancer Immunology Immunotherapy
16. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer
    Yaru Tian, Xiaoyang Zhai, Anqin Han, Hui Zhu, Jinming Yu · 2019 · Journal of Hematology & Oncology
17. Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice
    Yu Chen, Yanqing Pei, Jingyu Luo, Zhaoqin Huang, Jinming Yu, Xiangjiao Meng · 2020 · Frontiers in Immunology
18. Chemotherapeutic drugs: Cell death- and resistance-related signaling pathways. Are they really as smart as the tumor cells?
    Mojtaba Mollaei, Zuhair Mohammad Hassan, Fatemeh Khorshidi, Ladan Langroudi · 2021 · Translational Oncology
19. Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data
    Maurice Pérol, Enriqueta Felip, Urania G. Dafni, Letizia Polito, Navdeep Pal, Zoi Tsourti, Thanh G.N. Ton, D. Merritt, S. Morris, Rolf Arno Stahel et al. · 2022 · Annals of Oncology
20. AXL targeting restores PD-1 blockade sensitivity of STK11/LKB1 mutant NSCLC through expansion of TCF1+ CD8 T cells
    Li, Huiyu, Liu, Zhida, Liu, Longchao, Zhang, Hongyi, Han, Chuanhui, Girard, Luc, Park, Hyunsil, Zhang, Anli, Dong, Chunbo, Ye, Jianfeng et al. · 2022 · Cell Reports Medicine
21. Hyperprogression as a distinct outcome after immunotherapy
    Jesús Fuentes‐Antrás, Mariano Provencio, Eduardo Díaz‐Rubio · 2018 · Cancer Treatment Reviews
22. CRISPR/Cas9 and CAR-T cell, collaboration of two revolutionary technologies in cancer immunotherapy, an instruction for successful cancer treatment
    Hasan Mollanoori, Hojat Shahraki, Yazdan Rahmati, Shahram Teimourian · 2018 · Human Immunology
23. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases
    Anna‐Lena Volckmar, Jonas Leichsenring, Martina Kirchner, Petros Christopoulos, Olaf Neumann, Jan Budczies, Cristiano Manuel Morais de Oliveira, Eugen Rempel, Ivo Buchhalter, Regine Brandt et al. · 2019 · International Journal of Cancer
24. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer
    Roberto Ferrara, Martina Imbimbo, Reem Saleem Malouf, Sophie Paget‐Bailly, François Calais, Corynne Marchal, Virginie Westeel · 2021 · Cochrane Database of Systematic Reviews
25. A Prognostic Nomogram Combining Immune-Related Gene Signature and Clinical Factors Predicts Survival in Patients With Lung Adenocarcinoma
    Congkuan Song, Zixin Guo, Donghu Yu, Yujin Wang, Qingwen Wang, Zhe Dong, Weidong Hu · 2020 · Frontiers in Oncology
26. Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles
    Ju Hwan Cho · 2017 · Immune Network
27. Circulating immune cell phenotype dynamics reflect the strength of tumor–immune cell interactions in patients during immunotherapy
    Jason I. Griffiths, Pierre Wallet, Lance T. Pflieger, David Dean Stenehjem, Xuan Liu, Patrick A. Cosgrove, Neena A. Leggett, Jasmine A. McQuerry, Gajendra Shrestha, Maura Maria Rossetti et al. · 2020 · Proceedings of the National Academy of Sciences
28. Impact of high tumor mutational burden in solid tumors and challenges for biomarker application
    Mairead Geraldine McNamara, Timothy Jacobs, Ángela Lamarca, Richard A Hubner, Juan W. Valle, Eitan Amir · 2020 · Cancer Treatment Reviews
29. Overcoming the delivery problem for therapeutic genome editing: Current status and perspective of non-viral methods.
    T. Mashel, Y. Tarakanchikova, A. Muslimov, M. Zyuzin, A. Timin, K. Lepik, B. Fehse · 2020 · Biomaterials
30. The Confounders of Cancer Immunotherapy: Roles of Lifestyle, Metabolic Disorders and Sociological Factors
    Ravindra Pramod Deshpande, Sambad Sharma, Kounosuke Watabe · 2020 · Cancers
31. Immunotherapy in unresectable stage III non-small-cell lung cancer: state of the art and novel therapeutic approaches
    Francesco Cortiula, Bart J.T. Reymen, Solange Peters, Pierre Van Mol, Els Wauters, Johan Vansteenkiste, Dirk De Ruysscher, Lizza E.L. Hendriks · 2022 · Annals of Oncology
32. Activity of Nivolumab and Utility of Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for Advanced Non–Small-Cell Lung Cancer: A Prospective Observational Study
    Tomoya Fukui, Yuriko Okuma, Yoshiro Nakahara, Sakiko Otani, Satoshi Igawa, Masato Katagiri, Hisashi Mitsufuji, Masaru Kubota, Yasuhiro Hiyoshi, Mikiko Ishihara et al. · 2018 · Clinical Lung Cancer
33. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer
    Yanhui Chen, Quanxing Liu, Zhiming Chen, Yating Wang, Wanning Yang, Ying Hu, Wenbo Han, Hui Zeng, Haitao Ma, Jigang Dai et al. · 2019 · Journal of Experimental & Clinical Cancer Research
34. Immunotherapy in Non–Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence
    Antonio Passaro, Gianluca Spitaleri, Bishal Gyawali, Filippo de Marinis · 2019 · Journal of Clinical Oncology
35. Successful treatment with nivolumab for SMARCA4‐deficient non‐small cell lung carcinoma with a high tumor mutation burden: A case report
    Tomoyuki Naito, Shigeki Umemura, Hiroshi Nakamura, Yoshitaka Zenke, Hibiki Udagawa, Keisuke Kirita, Shingo Matsumoto, Kiyotaka Yoh, Seiji Niho, Noriko Motoi et al. · 2019 · Thoracic Cancer
36. Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer
    Diana Vesselinovitch Maslov, Karine Tawagi, Madhav KC, Victoria Simenson, Helen Yuan, Cameron Parent, Adi Bamnolker, Richa Goel, Zoë Blake, Marc Ryan Matrana et al. · 2021 · Journal for ImmunoTherapy of Cancer
37. Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC
    Scott Joseph Antonia, Ani Sarkis Balmanoukian, Julie Renee Brahmer, Sai‐Hong Ignatius Ou, Matthew David Hellmann, Sang-We Kim, Myung‐Ju Ahn, Dong‐Wan Kim, Martin E Gutierrez, Stephen V. Liu et al. · 2019 · Journal of Thoracic Oncology
38. Very early response of circulating tumour–derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non–small cell lung cancer
    Yuki Iijima, Yosuke Hirotsu, Kenji Amemiya, Yoshihiko Ooka, Hitoshi Mochizuki, Toshio Oyama, Takahiro Nakagomi, Yoshinori Uchida, Yoichi Kobayashi, Toshiharu Tsutsui et al. · 2017 · European Journal of Cancer
39. Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts
    Daniel N. Kazdal, Volker Endris, Michael Allgäuer, Mark Kriegsmann, Jonas Leichsenring, Anna‐Lena Volckmar, Alexander Harms, Martina Kirchner, Katharina Kriegsmann, Olaf Neumann et al. · 2019 · Journal of Thoracic Oncology
40. Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis
    Jing Jin, Lan Yang, Dan Liu, Weimin Li · 2020 · BMJ Open
41. Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities
    Xinan Wang, Giuseppe Lamberti, Alessandro Di Federico, Joao V. Alessi, Roberto Ferrara, M.L. Sholl, Mark Magdi Awad, Natalie I. Vokes, Biagio Ricciuti · 2024 · Annals of Oncology
42. The Cancer Immunotherapy Biomarker Testing Landscape
    Eric E. Walk, Sophia Louise Yohe, Amy Beckman, Andrew E. Schade, Mary M. Zutter, John D. Pfeifer, Anna Belinda Berry · 2019 · Archives of Pathology & Laboratory Medicine
43. Tumor mutational burden in lung cancer: a systematic literature review
    Connor Willis, Michelle Fiander, Dao Tran, Beata Korytowsky, John-Michael Thomas, Florencio Calderon, Teresa Maria Zyczynski, Diana I Brixner, David Dean Stenehjem · 2019 · Oncotarget
44. Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors
    Berland, Léa, Heeke, Simon, Humbert, Olivier, Macocco, Adam, Long-Mira, Elodie, Lassalle, Sandra, Lespinet-Fabre, Virginie, Lalvée, Salomé, Bordone, Olivier, Cohen, Charlotte et al. · 2019 · Journal of Thoracic Disease
45. DNA repair defects and implications for immunotherapy
    Katherine M. Bever, Dung Thi Le · 2018 · Journal of Clinical Investigation
46. Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy
    Lizza E.L. Hendriks, Étienne Rouleau, Benjamin Besse · 2018 · Translational Lung Cancer Research
47. Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
    Tokiyoshi Tanegashima, Yosuke Togashi, Koichi Azuma, Akihiko Kawahara, Ko Ideguchi, Daisuke Sugiyama, Fumio Kinoshita, Jun Akiba, Eiji Kashiwagi, Ario Takeuchi et al. · 2019 · Clinical Cancer Research
48. Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors
    Masayuki Takeda, Takayuki Takahama, Kazuko Sakai, Shigeki Shimizu, Satomi Watanabe, Hisato Kawakami, Kaoru Tanaka, Chihiro Sato, Hidetoshi Hayashi, Yoshikane Nonagase et al. · 2020 · The Oncologist
49. Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab
    Mioko Matsuo, Ryuji Yasumatsu, Muneyuki Masuda, Satoshi Toh, Takahiro Wakasaki, Kazuki Hashimoto, Masahiko Taura, Ryutaro Uchi, Takashi Nakagawa · 2019 · Oral Oncology
50. Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies
    Robert John Walsh, Ross Andrew Soo · 2020 · Therapeutic Advances in Medical Oncology
51. Pediatric patients with acute lymphoblastic leukemia generate abundant and functional neoantigen-specific CD8 + T cell responses
    Anthony Elston Zamora, Jeremy Chase Crawford, Emma Kaitlynn Allen, Xi-zhi J. Guo, Jesse Bakke, Robert A. Carter, Hossam Aly Abdelsamed, Ardiana Moustaki, Yongjin Li, Ti‐Cheng Chang et al. · 2019 · Science Translational Medicine
52. Time to dissect the autoimmune etiology of cancer antibody immunotherapy
    Michael Lawrence Dougan, Massimo Pietropaolo · 2020 · Journal of Clinical Investigation
53. Variation in the Assessment of Immune-Related Adverse Event Occurrence, Grade, and Timing in Patients Receiving Immune Checkpoint Inhibitors
    David Hsiehchen, Mary Katherine Watters, Rong Lü, Yang Xie, David E. Gerber · 2019 · JAMA Network Open
54. Hyperprogressive Disease in Patients with Non–Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of 18 F-FDG PET/CT
    Angelo Castello, Sabrina Rossi, Emanuela Mazziotti, Luca Toschi, Egesta Lopci · 2019 · Journal of Nuclear Medicine
55. Immunotherapy in nonsmall-cell lung cancer: current status and future prospects for liquid biopsy
    Elena Brozos-Vázquez, Roberto Díaz‐Peña, Jorge García, Luis León‐Mateos, Patricia Mondelo‐Macía, María Peña-Chilet, Rafael López‐López · 2020 · Cancer Immunology Immunotherapy
56. Role of Small Molecule Targeted Compounds in Cancer: Progress, Opportunities, and Challenges
    Guoqiang Sun, Dawei Rong, Zhouxiao Li, Guangshun Sun, Fan Wu, Xiao Li, Hongyong Cao, Ye Cheng, Weiwei Tang, Yangbai Sun · 2021 · Frontiers in Cell and Developmental Biology
57. Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer
    François Ghiringhelli, Frédéric Bibeau, Laurent Greillier, Jean-David Fumet, Alis Ilie, Florence Monville, Caroline Laugé, Aurélie Catteau, Isabelle Boquet, Amine Majdi et al. · 2023 · EBioMedicine
58. Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future Research
    Ravindran Kanesvaran, Raúl Córdoba, Ronald John Maggiore · 2018 · American Society of Clinical Oncology Educational Book
59. Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors
    Ryul Kim, Bhumsuk Keam, Sehui Kim, Miso Kim, Se Hyun Kim, Jin‐Wook Kim, Yu Jung Kim, Tae Min Kim, Yoon Kyung Jeon, Dong‐Wan Kim et al. · 2019 · BMC Cancer
60. Advances in the Treatment of Non–Small Cell Lung Cancer
    Shetal Arvind Patel, Jared Weiss · 2020 · Clinics in Chest Medicine
61. PLK1/vimentin signaling facilitates immune escape by recruiting Smad2/3 to PD-L1 promoter in metastatic lung adenocarcinoma
    Hay-Ran Jang, Sol‐Bi Shin, Chang-Hyeon Kim, Jae-Yeon Won, Rong Xu, Daeun Kim, Hyungshin Yim · 2021 · Cell Death and Differentiation
62. Systematic Review of PD-1/PD-L1 Inhibitors in Oncology: From Personalized Medicine to Public Health
    Elaine Chang, Lorraine Cheryl Pelosof, Steven J. Lemery, Yutao U. T. Gong, Kirsten B. Goldberg, Ann T. Farrell, Patricia Keegan, Janaki Veeraraghavan, Guo Wei, Gideon Michael Blumenthal et al. · 2021 · The Oncologist
63. Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1–Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042
    Aaron Scott Mansfield, Roy S. Herbst, Gilberto de Castro, Rina Hui, Nir Peled, Dong‐Wan Kim, Silvia Novello, Miyako Satouchi, Yi-Long Lung Cancer Wu, Edward B. Garon et al. · 2021 · JTO Clinical and Research Reports
64. An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure
    Wei Liu, Wenhua You, Zhenwei Lan, Yijiu Ren, Shuangshu Gao, Shuchao Li, Weiwei Chen, Chunyu Huang, Yong Zeng, Nengming Xiao et al. · 2024 · Cell Reports Medicine
65. The Resistance Mechanisms of Lung Cancer Immunotherapy
    Fen Wang, Shubin Wang, Qing Hua Zhou · 2020 · Frontiers in Oncology
66. Phenotype Switching and the Melanoma Microenvironment; Impact on Immunotherapy and Drug Resistance
    Sultana Mehbuba Hossain, Michael Roger Eccles · 2023 · International Journal of Molecular Sciences
67. Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies
    Suna Zhou, Haihua Yang · 2023 · Frontiers in Immunology
68. CD47: the next checkpoint target for cancer immunotherapy
    Ridong Feng, Zhao Hai, Jianguo Xu, Chongyang Shen · 2020 · Critical Reviews in Oncology/Hematology
69. Emerging biomarkers for immune checkpoint inhibition in lung cancer
    George Cyriac, Leena Gandhi · 2018 · Seminars in Cancer Biology
70. The predictive power of tumor mutational burden in lung cancer immunotherapy response is influenced by patients’ sex
    Shixiang Wang, Jing Zhang, Zaoke He, Kai Wu, Xuesong Liu · 2019 · International Journal of Cancer
71. Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer
    Tina Cascone, Jared J. Fradette, Monika Pradhan, Don Lynn Gibbons · 2021 · Cold Spring Harbor Perspectives in Medicine
72. Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients
    Marina Chiara Garassino, Alain Jonathan Gelibter, Francesco Grossi, Rita Chiari, Hector Josè Soto Parra, Stefano Cascinu, Francesco Cognetti, Daniele Turci, Livio Blasi, Carmelo Bengala et al. · 2018 · Journal of Thoracic Oncology
73. Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
    Ryo Sato, Kosuke Imamura, Shinya Sakata, Tokunori Ikeda, Yuko Horio, Shinji Iyama, Kimitaka Akaike, Shohei Hamada, Takayuki Jodai, Kei Nakashima et al. · 2019 · Journal of Clinical Medicine
74. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non–Small Cell Lung Cancer
    Yu Chen, Gang Chen, Jin Li, Yingying Huang, Yi Li, Jing Lin, Lizhu Chen, Jianping Lu, Yuqi Wang, Changxi Wang et al. · 2019 · JAMA Network Open
75. Allele Frequency–Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors
    Zhijie Wang, Jianchun Duan, Guoqiang Wang, Jing Zhao, Jiachen Xu, Jiefei Han, Zhengyi Zhao, Jun Zhao, Bo Zhu, Minglei Zhuo et al. · 2019 · Journal of Thoracic Oncology
76. Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
    Jiahang Mo, Xiao Hu, Lihu Gu, Bangsheng Chen, Parikshit Asutosh Khadaroo, Zefeng Shen, Lei Dong, Yuqi Lv, Marylin Nyaradzo Chitumba, Jiequan Liu · 2020 · World Journal of Surgical Oncology
77. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic
    Noelia Vilariño, Jordi Bruna, Joaquim Bosch‐Barrera, Manuel Valiente, Ernest Nadal · 2020 · Cancer Treatment Reviews
78. Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
    Aaron C. Tan, Stephen Joseph Bagley, Patrick Yung Wen, Michael K. Lim, Michael Platten, Howard Colman, David M. Ashley, Wolfgang Wick, Susan Marina Chang, Evanthia Galanis et al. · 2021 · Journal for ImmunoTherapy of Cancer
79. Immunotherapy in non-small cell lung cancer: Past, present, and future directions
    Salman Rafi Punekar, Elaine Shum, Cassandra Grello, Sally C. M. Lau, Vamsidhar Velcheti · 2022 · Frontiers in Oncology
80. Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma
    Hui Yu, Zhengming Chen, Karla V. Ballman, Mark A. Watson, Ramaswamy Govindan, Irena Lanc, David G. Beer, Raphael Bueno, Lucian R. Chirieac, Michael Herman Chui et al. · 2018 · Journal of Thoracic Oncology
81. Circulating miRNAs and PD-L1 Tumor Expression Are Associated with Survival in Advanced NSCLC Patients Treated with Immunotherapy: a Prospective Study
    Mattia Boeri, Massimo Milione, Claudia Proto, Diego Signorelli, Giuseppe Lo Russo, Carlotta Galeone, Carla Verri, Mavis Mensah, Giovanni Centonze, Antonia Martinetti et al. · 2019 · Clinical Cancer Research
82. Immunotherapy for the First-Line Treatment of Patients with Metastatic Non–Small Cell Lung Cancer
    Pablo Martínez, Solange Peters, Timothy A. Stammers, Jean‐Charles Soria · 2019 · Clinical Cancer Research
83. Advanced-Stage Non–Small Cell Lung Cancer: Advances in Thoracic Oncology 2018
    Jordi Remón, Myung‐Ju Ahn, Nicolas Girard, Melissa Lynne Johnson, Dong‐Wan Kim, Gilberto De Lima Lopes Jr., Rathi Narayana Pillai, Benjamin Solomon, Guillermo Javierre Villacampa, Qing Hua Zhou · 2019 · Journal of Thoracic Oncology
84. Stereotactic Ablative Radiotherapy Combined with Immune Checkpoint Inhibitors Reboots the Immune Response Assisted by Immunotherapy in Metastatic Lung Cancer: A Systematic Review
    Rodolfo Chicas-Sett, Ignacio Morales-Orue, Juan Castilla-Martinez, Juan Zafra, Andrea Kannemann, Jesus Blanco, Marta Lloret, Pedro C. Lara · 2019 · International Journal of Molecular Sciences
85. PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
    Hyojin Kim, Jin-Haeng Chung · 2019 · Journal of Pathology and Translational Medicine
86. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development
    Arie Regev, Mark Avigan, Alexandre Kiazand, John Moore Vierling, James H. Lewis, Stephanie O. Omokaro, Adrian M. Di Bisceglie, Robert J. Fontana, Herbert L. Bonkovsky, James W. Freston et al. · 2020 · Journal of Autoimmunity
87. The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives
    Shengbo Sun, Lanchun Liu, Jingkang Zhang, Liting Sun, Wenlong Shu, Zhengyang Yang, Hongwei Yao, Zhongtao Zhang · 2025 · Journal of Hematology & Oncology
88. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer
    Biagio Ricciuti, Sasha Kravets, Suzanne Eleanor Dahlberg, Renato Umeton, Adem Albayrak, Safiya J. Subegdjo, Bruce Evan Johnson, Mizuki Nishino, Lynette Marie Sholl, Mark Magdi Awad · 2019 · Journal for ImmunoTherapy of Cancer
89. Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients
    Peng Song, Dingding Zhang, Xiaoxia Cui, Li Zhang · 2020 · Thoracic Cancer
90. First line Immunotherapy for Non-Small Cell Lung Cancer
    Nicola Joseph Nasser, Miguel Gorenberg, Abed Agbarya · 2020 · Pharmaceuticals
91. Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials
    Qingyuan Huang, Hua Zhang, Josephine Hai, Mark A. Socinski, Eric Kian Saik Lim, Haiquan Chen, Justin Stebbing · 2017 · OncoImmunology
92. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC)
    Kazue Yoneda, Naoko Imanishi, Yoshinobu Ichiki, Fumihiro Tanaka · 2018 · Journal of UOEH
93. MicroRNAs in non‐small cell lung cancer: Gene regulation, impact on cancer cellular processes, and therapeutic potential
    Hannah Elizabeth Petrek, Ai‐Ming Yu · 2019 · Pharmacology Research & Perspectives
94. Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)
    Si‐Yang Maggie Liu, Yi-Long Lung Cancer Wu · 2020 · Expert Opinion on Investigational Drugs
95. Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer
    Ruth Perets, Jair Bar, Drew Warren Rasco, Myung‐Ju Ahn, Kiyotaka Yoh, D.-W. Kim, Adnan M. Nagrial, Miyako Satouchi, Daniel Lee, David Robert Spigel et al. · 2020 · Annals of Oncology
96. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non‐small‐cell lung cancer: A systematic review and meta‐analysis
    Chengdi Wang, Wenliang Qiao, Yuting Jiang, Min Zhu, Jun Shao, Tao Wang, Dan Liu, Weimin Li · 2019 · Journal of Cellular Physiology
97. The effect of smoking status on efficacy of immune checkpoint inhibitors in metastatic non-small cell lung cancer: A systematic review and meta-analysis
    Linzheng Dai, Bo Jin, Tingting Liu, Jun Chen, Guang Li, Jun Dang · 2021 · EClinicalMedicine
98. Immune-based combination therapy to convert immunologically cold tumors into hot tumors: an update and new insights
    Jiaojiao Ni, Zizhen Zhang, Ming-jie Ge, Jingyu Chen, Wei Zhuo · 2022 · Acta Pharmacologica Sinica
99. Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
    Hongxing Shen, Eddy Shih-Hsin Yang, M. Conry, John B. Fiveash, Carlo M. Contreras, James A. Bonner, Lewis Z. Shi · 2019 · Genes & Diseases
100. Commensal microbiota contributes to predicting the response to immune checkpoint inhibitors in non‐small‐cell lung cancer patients
     Chufeng Zhang, Jixin Wang, Zhongwen Sun, Yufeng Cao, Zhengshuai Mu, Xuming Ji · 2021 · Cancer Science